|Publication number||US7341840 B2|
|Application number||US 11/218,281|
|Publication date||Mar 11, 2008|
|Filing date||Sep 1, 2005|
|Priority date||Mar 5, 2003|
|Also published as||US7803557, US20060024758, US20090180961, WO2004078143A2, WO2004078143A3|
|Publication number||11218281, 218281, US 7341840 B2, US 7341840B2, US-B2-7341840, US7341840 B2, US7341840B2|
|Inventors||Charles N. Serhan, Makoto Arita|
|Original Assignee||The Brigham And Women's Hospital, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (99), Non-Patent Citations (99), Referenced by (31), Classifications (22), Legal Events (3)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is a continuation of International Application No. PCT/US2004/006766 filed Mar. 5, 2004, which claims priority to U.S. provisional application No. 60/452,244, filed Mar. 5, 2003, the contents of which are incorporated in their entirety by reference.
The work leading to this invention was supported in part by National Institutes of Health (NIH) grants GM38765, DK60583 and P01-DE13499. The U.S. Government therefore may have certain rights in the invention.
This invention relates to the identification and uses of receptors that mediate anti-inflammatory activity, particularly to anti-inflammatory activity mediated by eicosapentaenoic acid analogs, and to uses of such receptors to screen candidate substances for anti-inflammatory activity.
Clinical assessment of dietary supplementation therapy with omega-3 polyunsaturated fatty acids (w-3 PUFA) indicate that they have a beneficial impact in certain human diseases (1). Their molecular mechanisms of action in reducing local inflammation has remained unclear. w-3 PUFAs are held to act via several possible mechanisms, such as preventing conversion of arachidonic acid to proinflammatory eicosanoids, or serving as an alternative substrate for 5-lipoxygenase to produce less potent 5-series leukotrienes (2). Of interest, fish leukocytes rich in w-3 PUFA generate eicosanoids from eicosapentaenoic acid (EPA; C20:5 w-3) that play signaling roles (3). However, the appropriate receptor site(s) has remained unidentified.
There is a need in the art for the identification of the receptor site(s) that interact with noel eicosanoids to help better understand the mode of action of such therapeutic agents.
The essential fatty acid eicosapentaenoic acid (EPA) present in fish oils displays beneficial effects in a range of human disorders associated with inflammation including cardiovascular disease. Resolvin E1, a recently identified oxygenated product of EPA, a resolving analog, was prepared by total synthesis and in nanomolar range proved to dramatically reduce dermal inflammation, peritonitis, splenic dendritic cell migration and interleukin-12 production. A receptor for resolvin analogs, for example Resolvin E1 (denoted Reso-R1), that signals to attenuate cytokine induced nuclear factor (NF)-kB activation was identified. The results demonstrate novel counter-regulatory mechanisms in inflammation via receptor-ligand activation and provide the first evidence that EPA is a precursor to potent endogenous anti-inflammatory and endogenous host protective signals.
In one aspect, the invention provides a method for screening a candidate substance for anti-inflammatory activity that includes contacting a cell that expresses the Reso E receptor with the candidate substance and detecting a biological activity mediated by the Reso E receptor. As used herein, a Reso E receptor (Reso ER) is a polypeptide sequence with a receptor activity, and which in various embodiments, has at least 50%, at least 60%, at least 70% or at least about 80% identity with the Reso ER sequences according to SEQ. ID NO: 1; SEQ. ID NO: 2; SEQ. ID NO: 3 of
In another aspect, the invention provides a method of identifying a receptor that mediates an anti-inflammatory activity of a resolvin substance that includes introducing a nucleic acid configured to express a G-protein coupled receptor (GPCR) into a cell that does not endogenously express the GPCR, contacting the cell with a substance comprising a resolvin; and detecting that the cell has a reduced cytokine induced activation of a NF-kB transcription factor relative to a cell not contacted by the substance. As used herein, in one embodiment, a GPCR is a polypeptide sequence having at least 30%, or at least 40% or at least 50% or at least 60% or at least 70%, or at least about 80% identical to the Reso ER sequences defined above, which has at least 7 membrane spanning domains determinable by a Kyton-Doolittle hydropathy plot, and which has an biological activity coupled to a GTP binding activity of a G-protein. In another embodiment, a GPCR sequence has at least 60%, or at least 70%, or at least about 80% sequence identity within the second intracellular loop of the mouse, rat, or human, Reso ER, or human ALX sequences depicted in
In another aspect, the invention provides a method for screening a candidate substance for anti-inflammatory activity that includes detecting that the candidate substance alters an activity mediated by a GPCR receptor.
In another aspect, the invention provides method for identifying a substance that interacts with a receptor that mediates an anti-inflammatory activity that includes interacting a candidate substance with a receptor that reduces cytokine induced (NF)-κB activation.
In yet another aspect, the invention provides an isolated nucleic acid operably configured to express a nucleic acid that encodes a sufficient amount of a resolvin receptor polypeptide to mediate a biological response of the polypeptide when introduced into a cell. As used herein, a “resolvin receptor” is a receptor that interacts with any derivative of EPA that elicits an anti-inflammatory response.
In still another aspect, the invention provides a method of identifying a receptor that mediates an anti-inflammatory activity that includes, providing a small interfering RNA (siRNA) against a nucleic acid that encodes a candidate receptor, expressing the siRNA in a cell that expresses the candidate receptor, subjecting the cell to a condition that induces pro-inflammatory response, and detecting whether expressing the siRNA in the cell increases the pro-inflammatory response relative to a cell subjected to the condition but not expressing the siRNA. In one example embodiment, the pro-inflammatory response is increased production of a cytokine that mediates the pro-inflammatory response. In a more particular embodiment, the cytokine is IL-12.
While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. As will be realized, the invention is capable of modifications in various obvious aspects, all without departing from the spirit and scope of the present invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.
In the detailed description that follows, citation is made to various references that may aid one of skill in the art to understand or practice the invention in its fullest scope. Each such reference is incorporated herein by reference, to the extent the teaching of those references do not conflict with the teachings provided herein.
Clinical assessment of dietary supplementation with omega-3 polyunsaturated fatty acids (w-3 PUFA) indicate their beneficial impact in certain human diseases particularly those in which inflammation is suspected as a key component in pathogenesis (1-3). Their molecular bases of action in reducing disease and local inflammation is important and of interest given the heightened awareness that inflammation and resolution is a major mechanisms in many diseases including cardiovascular disease, arthritis, Alzheimer's disease, asthma and periodontitis (4,5). w-3 PUFAs are widely held to act via several possible mechanisms, such as preventing conversion of arachidonate to proinflammatory eicosanoids, or serving as an alternative substrate producing less potent products (1). Of interest, fish leukocytes rich in w-3 generate mediators from eicosapentaenoic acid (EPA) that play signaling roles (6). However, the pathophysiological role of leukotriene and prostanoid-like compounds from EPA remains uncertain in humans as many of these molecules' role(s) are unknown.
Recently, the present inventors discovered a novel family of aspirin-triggered bioactive lipids biosynthesized during the spontaneous resolution phase of acute inflammation in vivo. This family of bioactive lipids have been termed the Resolvins (resolution-phase interaction products), are described in more detail in U.S. patent application Ser. No. 10/639,714, filed Aug. 12, 2003, entitled “Resolvins: Biotemplates for Novel Therapeutic Interventions” and in PCT application No. PCT/US03/25336, filed on Aug. 12, 2003 and entitled the same, which are incorporated herein by reference in their entirety. The Resolvins are potent autacoids, which now can provide molecular means that underlie w-3 PUFA's protective actions (7,8). At local sites, aspirin treatment enables EPA conversion to the novel 18R series of oxygenated products that carry potent counterregulatory signals. One of the main compounds of this 18R series, namely 5,12,18R-trihydroxyeicosapentaenoic acid (termed Resolvin E1) can arise via cell-cell interactions in murine inflammatory exudates, also exemplified with human vascular endothelium carrying aspirin-acetylated cyclooxygenase (COX)-2 and leukocytes possessing 5-lipoxygenase(LO) (7). Here, Resolvin E1 was generated in healthy human volunteers given EPA and aspirin, plasma values ranging 0.1 to 0.4 ng/ml for 6 donors using liquid chromatography-tandem mass spectrometry (LC-MS/MS) (
To assign the complete stereochemistry of the main 18R series Resolvin E1 and establish its biological activities, biogenic Resolvin E1 was prepared (7), and matched with synthetic Resolvin E1 (5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid) having complete stereochemistry that was prepared by total organic synthesis from isomerically pure precursors (
Administration of as little as 100 ng/mouse of synthetic Resolvin E1 stopped leukocyte infiltration into inflammatory loci by 50-70% in TNF-a induced dorsal air pouch, which proved to be as potent as the biogenic material (
The murine airpouch is widely used to assess dermal inflammation and arthritis (
Resolvin E1 and Lipoxin (LX) A4 have different structures, are formed via different biosynthetic pathways and precursors (EPA vs arachidonate), yet they appear to share redundant beneficial properties that dampen excessive leukocyte recruitment (12), hence the present invention is based, at least in part, on recognizing that Resolvin E1 receptors share similar structural features to LO-derived eicosanoid receptors such as LXA4 receptor (ALX) and Leukotriene B4 receptor (BLT) (13).
Resolvin E1 gave concentration dependent inhibition of TNF-a induced NF-kB activation with an EC50 of ˜1.0 nM in Reso ER1 transfected cells but not in mock transfected cells (
Tissue distribution of human Reso ER1 was determined with dot blots containing mRNAs from human tissues that showed expression of Reso ER1 in several tissues such as cardiovascular system, brain, kidney, gastrointestinal tissues and myeloid tissues as is illustrated in
Given expression of human Reso ER1 in APCs, and since APC function is influenced by dietary w-3 PUFA supplementation (18), the activity of Resolvin E1 on APC function was examined using a microbial pathogen model. Injection of pathogen extract derived from Toxoplasma gondii (STAg) causes activation of splenic dendritic cells (DCs) to mobilize to T cell enriched areas where they produce high amounts of IL-12 (19). Addition of increasing concentrations of Resolvin E1 to isolated mouse splenic CD11c+DCs markedly inhibited IL-12p40 production by STAg within the nanomolar range (
siRNA experiments were carried out to reduce Reso ER1 in splenic DCs. The mouse ResoER receptor (17), which shares 80.3% identity with human Reso ER1, was also present in splenic DCs. Resolvin El's action in regulating IL-12 production from DCs was eliminated by treatment with a siRNA specific for the mouse Reso ER1 (
Acute inflammation is a protective host response to foreign challenge or tissue injury that could lead to, if unopposed, loss of tissue structure as well as function. In many chronic disorders, prolonged and unresolved inflammation is believed to contribute to pathogenesis (4). Resolution of inflammation is an active process controlled by endogenous mediators that can counterregulate pro-inflammatory gene expression and cell trafficking, as well as stimulate inflammatory cell clearance (11,20). The observation that cytokines upregulated Reso ER1 as well as COX-2 in monocytes indicates that in scenarios where COX-2 is induced during inflammation, monocytes as well as endothelial cells treated with aspirin can also potentially convert w-3 EPA into Resolvin E1 in concert with PMN (7), that may serve an autocrine and/or paracrine message to terminate further NF-kB activation and cytokine production in a temporal and spatially regulated fashion. Resolvin E1 is generated in healthy volunteers taking EPA and aspirin (
Studies reported here were performed using protocols approved by Harvard Medical Area Standing Committee on Animals and human subjects in accordance with the Brigham and Women's Human Research Committee.
LC-MS/MS Analysis of Resolvin E1
Human plasma samples were collected at 4 hours after oral administration of fish oil supplement (Fish Oil Concentrate, Walgreens) containing EPA (1 g) and DHA (0.7 g) followed by aspirin (160 mg) at 3 h in six healthy volunteers. Plasma samples were extracted by C18 solid phase extraction with d4-LTB4 (Cascade) as internal standard for LC-MS/MS analysis (7) using a Finnigan LCQ liquid chlomatography ion trap tandem mass spectrometer equipped with a LUNA C18-2 (100×2 mm×5 mm) column and UV diode array detector using mobile phase (methanol:water:acetate at 65:35:0.01) from 0 to 8 min, ramped to methanol 8 to 30 min, with a 0.2 ml/min flow rate.
Murine Dorsal Air-Pouch Model
Dorsal air pouches were raised on male FvB mice (6-8 wk) by injecting 3 ml of sterile air subcutaneously on days 0 and 3. On day 6, 100 ng/mouse of compounds were injected into tail vein. Inflammation in the air-pouch was induced by intrapouch injection of mouse recombinant TNF-a (100 ng/pouch), and pouch lavages were collected at 4 h and cells were enumerated.
Zymosan Induced Peritonitis
For peritonitis, 100 ng/mouse of Resolvin E1 or related structures was injected into tail vein and followed by 1 ml zymosan A (1 mg/ml) into-the peritoneum. Peritoneal lavages were collected at 2 h and cells were enumerated.
GPCR cDNAs and Phylogenetic Tree
GPCR cDNAs were cloned by RT-PCR using specific primers designed according to the GenBank™ database; human FPR(P21462), ALX(P25090), FPRL2(P25089), GPR1(A55733), GPR32(075388), Dez(Q99788), CRTH2(Q9Y5Y4), C3AR(Q16581), C5AR(P21730), BLT1(Q15722). mouse Reso ER1 (U79525). The phylogenetic tree was constructed using the “All Program” at the Computational Biochemistry Server at ETHZ (http://cbrg.inf.ethz.ch/Server/AllAll.html).
NF-kB Reporter Gene Assay
HEK293 cells (1.0′ 105 cells) were transiently transfected with 50 ng pNF-kB-luciferase (Stratagene), 500 ng of either pcDNA3 or pcDNA3-GPCRs and the internal standard pRL-TK (Promega) using Superfect transfection reagent (Qiagen). After 24 h, cells were exposed to the test compounds for 30 min, stimulated with recombinant human TNF-a (1.0 ng/ml, BD Pharmingen) for 5 h. Luciferase activity was measured by the Dual-Luciferase reporter assay system (Promega). Basal induction of luciferase activity by TNF-a was >150-fold in this system. Efficient expression of GPCRs to the cell surface was observed by immunostaining using HA-tagged GPCR constructs. For PTX treatment, HEK293 cells were treated with PTX (200 ng/ml) for 24 h before stimulation.
[35S]-GTPgS Binding Assay
HEK293 cells stably expressing human Reso ER1 were homogenized in ice-cold TED buffer (20 mM Tris-HCl pH7.5/1 mM EDTA/5 mM MgCl2/1 mM DTT). Membrane fraction (10 mg) was incubated in 400 ml of GTP-binding buffer (50 mM Hepes, pH7.5/100 mM NaCl/1 mM EDTA/5 mM MgCl2/1 mM DTT) containing 0.1 nM [35S]-GTPgS (>1000 Ci/mmol, Amersham) and 10 mM GDP for 30 min at 30° C. The bound and unbound [35S]-GTPgS was separated by rapid filtration through GF/C filters, and counted by liquid scintillation. Nonspecific binding was determined in the presence of 50 mM unlabeled GTPgS. Basal [35S]-GTP-gS binding was 81.6+1.5 cpm/mg protein.
Dot Blot Hybridization and RT-PCR
Hybridization to MTE array (CLONTECH) was carried out using 1.1 kb.p. fragment encoding open reading frame of Reso ER1 following the manufacturer's protocol. Primers used in amplifications are 5′-ATGAGAATGGAGGATGAAGA-3′ and 5′-TCAAAGCATGCCGGTCTCC-3′ for human Reso ER1, 5′-ATGGAGTACGACGCTTA CAA-3′ and 5′-TCAGAGGGTACTGGTCTCCTTCT-3′ for mouse Reso ER1, 5′-GCTGACTATGGCTACAAAAGCTGG-3′ and 5′-ATGCTCAGGGACTTGAGGAGG GTA-3′ for COX-2, 5′-GACCACAGTCCATGACATCACT-3′ and 5′-TCCACCACCC TGTTGCTGTAG-3′ for glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Amplified products were confirmed by direct sequencing.
MAP Kinase Activation
MAP kinase activation in monocytes and HEK293 cells after treatment with 100 nM of each compound was determined. After incubations, cells were lysed in cold lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 1.0% NP-40, 0.5% sodium deoxycolate, 10 mM NaF, 10 mM sodium pyrophosphate) containing protease inhibitor cocktail (Sigma). 40 mg of protein was separated on SDS-PAGE and immunoblot was performed using anti-phospho-p44/42 MAP kinase (Cell Signaling) and anti-ERK (Santa Cruz) antibodies. For PTX treatment, HEK-Reso ER1 cells were incubated with or without PTX (200 ng/ml) for 24 h at 37° C. and ERK activation was monitored by addition of Resolvin E1 (100 nM) for 5 min.
Activation of Spleen Dendritic Cells with Pathogen Extract (STAg)
Experiments were performed essentially as in (19). STAg was prepared from sonicated T. gondii (RH strain) tachzoytes. For isolated DC experiments, 70-85% CD11c positive DCs were isolated from spleen. CD11c+DC suspensions (1.0×106 cells/ml) were spread into 96-well plates and incubated for 24 h with Resolvin E1 before the addition of STAg (5 mg/ml). After overnight culture, supernatants were collected and EL-12p40 was measured with a sandwich ELISA. For in vivo treatments, C57BL/6 mice (n=3 per group) were injected intravenously with 100 ng Resolvin E1. After 18 h the animals were challenged intraperitoneally with PBS (0.2 ml/mouse), STAg (5 mg/ml) and sacrificed after an additional 6 h. CD11c+DCs were isolated from spleen and IL12-p40 secretion was measured at 24 h. For DC migration, Splenic frozen section from mice treated as above but given 10 mg of Resolvin E1 or vehicle were stained for CD11c and counterstained with hematoxylin.
Chemically synthesized siRNA for mouse Reso ER1 (5′-AACACUGUGUGGUUUGUCAACdTdT-3′) and Non-specific control IX siRNA (5′-AUUGUAUGCGAUCGCAGACUU-3′) were from Dharmacon Research. Spleen cells (1.0×106 cells/ml) were transfected using Chariot (Active Motif) following manufacturers' instructions. Briefly, siRNA was mixed with Chariot transfection reagent and incubated at room temperature for 30 minutes. Spleen cells were plated in serum-free RPMI medium, 200 ng siRNA/Chariot solution was added and incubated for 2 h at 37° C., followed by adding 10% FCS RPMI to the cultures. To assure effective inhibition of gene expression, cells were further incubated for 30 h at 37° C. before STAg stimulation.
For note (a) LC-MS/MS was performed with Finnigan LCQ liquid chromatography ion trap tandem mass spectrometer equipped with a LUNA C18-2 (100×2 mm×5 mm) column and a UV diode array detector using isocratic mobile phase (MeOH:H2O:AcOH at 65:35:0.01 (vol:vol:vol), with a 0.2 ml/min flow rate). For note (b) GC-MS was performed with a Hewlett-Packard 6890 equipped with a HP 5973 mass detector. A HP5MS cross-linked 5% ME siloxane column (30 m×0.25 mm×0.25 mm) was employed with a temperature program. The helium flow rate was 1.0 ml/min and the initial temperature was 150° C., followed by 230° C. (2 min), and 280° C. (10 min). Trimethylsilyl derivatives were prepared with each compound following treatment with diazomethane. For note (c) spectra were recorded in methanol.
Inhibition of Leukocyte Infiltration in Murine Zymosan-Induced Peritonitis.
18R-HEPE (100 ng), Resolvin E1 (100 ng), or Indomethacin (100 ng) was injected intravenously into mouse tails followed by zymosan A into the peritoneum. Mice were sacrificed, and peritoneal lavages were collected (2 h) and cells enumerated (n=3).
Effect of Pertussis Toxin (PTX) on Resolvin E1-Induced ERK Activation (a) and NF-kB Inhibition (b).
siRNA-Directed Silencing of Reso ER1 Expression in Hek293 Cells.
Hek293 cells (5.0×105 cells) were transiently co-transfected with haemagglutinin(HA)-tagged mouse Reso ER1 expression plasmid (pHM6-mReso ER1, 0.5 mg) and siRNA (1.5 mg) using Superfect (Qiagen). After 48 h, cells were harvested and stained with anti-HA monoclonal antibody 3F10 and FITC-anti-rat IgG (Roche) and analyzed for cell-surface expression of HA-mReso ER1 by flow cytometry.
1. De Caterina, R., Endres, S., Kristensen, S. D., Schmidt, E. B. eds. N-3 fatty acids and vascular disease. Bi&Gi Publishers, Verona (1993).
2. Marchioli, R. et al. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354, 447-455 (1999).
3. Albert, C. M. et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N. Engl. J. Med. 346, 1113-1118 (2002).
4. Weiss, U. eds. Insight: Inflammation, Nature 420, 845 (2002).
5. Funk, C. D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294, 1871-1875 (2001).
6. Rowley, A. F., Hill, D. J., Ray, C. E., Munro, R. Haemostasis in fish, an evolutionary perspective. Thromb. Haemost. 77, 227-233 (1997).
7. Serhan, C. N. et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197-1204 (2000).
8. Serhan, C. N. et al. Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037 (2002).
9. Clish, C. B. et al. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl. Acad. Sci. USA 96, 8247-8252 (1999).
10. Lawrence, T., Willoughby, D. A., Gilroy, D. W. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nature Reviews. 2, 787-795 (2002).
11. Tessier, P. A. et al. Chemokine networks in vivo. Involvement of C—X—C and C—C chemokines in neutrophil extravasation in vivo in response to TNF-a. J. Immunol. 159, 3595-3602 (1997).
12. McMahon, B., Mitchell, S., Brady, H. R., Godson, C. Lipoxins: revelations on resolution. Trends Pharmacol. Sci. 22, 391-395 (2001).
13. Yokomizo, T., Izumi, T., Chang, K., Takuwa, Y., Shimizu, T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387, 620-624 (1997).
14. Gewirts, A. T. et al. Lipoxin A4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J. Immunol. 168, 5260-5267 (2002).
15. Samson, M. et al. ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. Eur. J. Immunol. 28, 1689-1700 (1998).
16. Kopp, E., Ghosh, S. Inhibition of NF-kB by sodium salicylate and aspirin. Science 265, 956-959 (1994).
17. Methner, A. et al. A novel G protein-coupled receptor with homology to neuropeptide and chemoattractant receptors expressed during bone development. Biochem. Biophys. Res. Commun. 233, 336-342 (1997).
18. Endres, S. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N. Engl. J. Med. 320, 265-271 (1989).
19. Aliberti, J., Hieny, S., reis e Sousa, C., Serhan, C. N., Sher, A. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nature Immunol. 3, 76-82 (2002).
20. Nathan, C. Points of control in inflammation. Nature 420, 846-852 (2002).
21. Topper, J. N., Cai, J., Falb, D., Gimbrone, M. A., Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganase superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl. Acad. Sci. USA 93, 10417-10422 (1996).
22. Cheng, Y. et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296, 539-541 (2002).
23. Yokomizo, T., Kato, K., Terawaki, K., Izumi, T., Shimizu, T. A second leukotriene B4 receptor, BLT2: A new therapeutic target in inflammation and immunological disorders. J. Exp. Med. 192, 421-431 (2000).
24. Serhan, C. N. Endogenous chemical mediators in anti-inflammation and pro-resolution. Curr. Med. Chem. 1, 177-192 (2002).
25. Capdevila, J. H. et al. The highly stereoselective oxidation of polyunsaturated fatty acids by cytochrome P450BM-3. J. Biol. Chem. 271, 22663-22671 (1996).
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4201211||Jul 12, 1977||May 6, 1980||Alza Corporation||Therapeutic system for administering clonidine transdermally|
|US4442099||Nov 27, 1981||Apr 10, 1984||Research Corporation||Leukotriene analogues|
|US4567290||Sep 1, 1983||Jan 28, 1986||Research Corporation||Leukotriene analogues|
|US4576758||Jun 1, 1984||Mar 18, 1986||The Upjohn Company||Anti-inflammatory lipoxin B analogs|
|US4666701||Mar 13, 1986||May 19, 1987||Efamol Limited||Pharmaceutical and dietary compositions|
|US4710521||Jul 25, 1986||Dec 1, 1987||The Celotex Corporation||Catalyst mixtures for polyisocyanurate foam|
|US4759880||Sep 27, 1984||Jul 26, 1988||Research Corporation||Alkanoarachidonic acids|
|US4810424||Oct 9, 1987||Mar 7, 1989||The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University||Method for the recovery of 12-(S)-hydroxyeicosapentaenoic acid from the red alga murrayella periclados|
|US5087790||Jun 12, 1991||Feb 11, 1992||University Of Southern California||Method for olefination of carbonyl compounds using titanocene derivatives|
|US5136501||May 26, 1989||Aug 4, 1992||Reuters Limited||Anonymous matching system|
|US5177046||Nov 18, 1991||Jan 5, 1993||Air Products And Chemicals, Inc.||Amine-boron adducts as reduced odor catalyst compositions for the production of polyurethanes|
|US5409955||May 13, 1993||Apr 25, 1995||Bockow; Barry I.||Compositions and methods for inhibiting uterine contractility|
|US5411988||Oct 27, 1993||May 2, 1995||Bockow; Barry I.||Compositions and methods for inhibiting inflammation and adhesion formation|
|US5441951||Jun 15, 1994||Aug 15, 1995||Brigham & Women's Hospital||Lipoxin compounds|
|US5594732||Mar 3, 1995||Jan 14, 1997||Intecom, Incorporated||Bridging and signalling subsystems and methods for private and hybrid communications systems including multimedia systems|
|US5604258||Jun 24, 1992||Feb 18, 1997||Women's And Children's Hospital Adelaide||Methods for treating malaria and other diseases|
|US5648512||May 31, 1995||Jul 15, 1997||Brigham & Womens Hospital||Lipoxin compounds|
|US5709855||Sep 22, 1995||Jan 20, 1998||Bockow; Barry I.||Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain|
|US5752238||Nov 3, 1994||May 12, 1998||Intel Corporation||Consumer-driven electronic information pricing mechanism|
|US5756789||Jun 3, 1996||May 26, 1998||Texaco, Inc.||Synthesis of metal--containing aluminophosphates with layered structure|
|US5814599||Aug 4, 1995||Sep 29, 1998||Massachusetts Insitiute Of Technology||Transdermal delivery of encapsulated drugs|
|US5842040||Jun 18, 1996||Nov 24, 1998||Storage Technology Corporation||Policy caching method and apparatus for use in a communication device based on contents of one data unit in a subset of related data units|
|US5845265||Nov 7, 1995||Dec 1, 1998||Mercexchange, L.L.C.||Consignment nodes|
|US5846974||Dec 3, 1997||Dec 8, 1998||Eli Lilly And Company||Method for treating substance abuse withdrawal|
|US5870717||Nov 13, 1995||Feb 9, 1999||International Business Machines Corporation||System for ordering items over computer network using an electronic catalog|
|US5878400||Jun 17, 1996||Mar 2, 1999||Trilogy Development Group, Inc.||Method and apparatus for pricing products in multi-level product and organizational groups|
|US5878423||Apr 21, 1997||Mar 2, 1999||Bellsouth Corporation||Dynamically processing an index to create an ordered set of questions|
|US5890138||Aug 26, 1996||Mar 30, 1999||Bid.Com International Inc.||Computer auction system|
|US5896379||Aug 26, 1996||Apr 20, 1999||Motorola, Inc.||Network node for packet switching with selective data processing and method therefor|
|US5932598||Jan 12, 1998||Aug 3, 1999||G. D. Searle & Co.||Prodrugs of benzenesulfonamide-containing COX-2 inhibitors|
|US5946467||Nov 7, 1996||Aug 31, 1999||Novell, Inc.||Application-level, persistent packeting apparatus and method|
|US6030715||Oct 9, 1997||Feb 29, 2000||The University Of Southern California||Azlactone-related dopants in the emissive layer of an OLED|
|US6030917||Jul 22, 1997||Feb 29, 2000||Symyx Technologies, Inc.||Combinatorial synthesis and analysis of organometallic compounds and catalysts|
|US6048897||Sep 13, 1996||Apr 11, 2000||Brigham And Women's Hospital||Lipoxin compounds and their use in treating cell proliferative disorders|
|US6069109||Jul 1, 1998||May 30, 2000||Union Carbide Chemicals & Plastics Technology Corporation||Process for the production of half-sandwich transition metal based catalyst precursors|
|US6117911||Apr 9, 1998||Sep 12, 2000||Neorx Corporation||Compounds and therapies for the prevention of vascular and non-vascular pathologies|
|US6201022||Mar 27, 1997||Mar 13, 2001||Myorx, Inc.||Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid|
|US6232467||Jun 27, 1997||May 15, 2001||University Of Southern California||Method for the synthesis of amines and amino acids with organoboron derivatives|
|US6259699||Dec 30, 1997||Jul 10, 2001||Nexabit Networks, Llc||System architecture for and method of processing packets and/or cells in a common switch|
|US6272474||Feb 8, 1999||Aug 7, 2001||Crisostomo B. Garcia||Method for monitoring and trading stocks via the internet displaying bid/ask trade bars|
|US6316648||May 11, 1999||Nov 13, 2001||The Brigham And Women's Hospital, Inc.||Lipoxin compounds and their use in treating cell proliferative disorders|
|US6336138||Aug 25, 1998||Jan 1, 2002||Hewlett-Packard Company||Template-driven approach for generating models on network services|
|US6377937||May 28, 1998||Apr 23, 2002||Paskowitz Associates||Method and system for more effective communication of characteristics data for products and services|
|US6397212||Mar 4, 1999||May 28, 2002||Peter Biffar||Self-learning and self-personalizing knowledge search engine that delivers holistic results|
|US6415270||Nov 15, 1999||Jul 2, 2002||Omnihub, Inc.||Multiple auction coordination method and system|
|US6427132||Aug 31, 1999||Jul 30, 2002||Accenture Llp||System, method and article of manufacture for demonstrating E-commerce capabilities via a simulation on a network|
|US6428900||Mar 9, 2000||Aug 6, 2002||Ato Findley, Inc.||Sulfonated copolyester based water-dispersible hot melt adhesive|
|US6569075||Oct 1, 2001||May 27, 2003||Brigham And Women's Hospital||Lipoxin compounds and their use in treating cell proliferative disorders|
|US6602817||Oct 22, 1999||Aug 5, 2003||University Of Southern California||Combination approach to chiral reagents or catalysts having amine or amino alcohol ligands|
|US6620919||Jun 19, 2002||Sep 16, 2003||The Brigham And Women's Hospital||Lipoxin compounds and their use in treating cell proliferative disorders|
|US6635776||Dec 2, 2002||Oct 21, 2003||The Brigham And Women's Hospital||Lipoxin compounds and their use in treating cell proliferative disorders|
|US6653493||Mar 9, 2001||Nov 25, 2003||The Brigham And Women's Hospital||Lipoxin compounds and their use in treating cell proliferative disorders|
|US6670396||Feb 16, 2001||Dec 30, 2003||Brigham And Women's Hospital||Aspirin-triggered lipid mediators|
|US6750360||Mar 9, 2001||Jun 15, 2004||Bringham And Women's Hospital||Lipoxin compounds and their use in treating cell proliferative disorders|
|US6887901||Mar 18, 2003||May 3, 2005||Brigham & Women's Hospital, Inc.||Lipoxin compounds and their use in treating cell proliferative disorders|
|US20010023500||Jan 11, 2001||Sep 20, 2001||Brigham And Women's Hospital||Leukotriene B4 receptor transgenic mice|
|US20020010351||Mar 9, 2001||Jan 24, 2002||Serhan Charles N.||Lipoxin compounds and their use in treating cell proliferative disorders|
|US20020031882||Mar 5, 1999||Mar 14, 2002||Tetsuya Uchida||Method for manufacturing a semiconductor integrated circuit of triple well structure|
|US20020045579||Oct 5, 2001||Apr 18, 2002||Madara James L.||Modulation of inflammation related to columnar epithelia|
|US20020055538||Feb 16, 2001||May 9, 2002||Serhan Charles N.||Aspirin-triggered lipid mediators|
|US20020082435||Mar 9, 2001||Jun 27, 2002||Serhan Charles N.||Lipoxin compounds and their use in treating cell proliferative disorders|
|US20020091279||Mar 9, 2001||Jul 11, 2002||Serhan Charles N.||Lipoxin compounds and their use in treating cell proliferative disorders|
|US20020094549||Feb 27, 2002||Jul 18, 2002||Serhan Charles N.||Screening methods for presqualene diphosphate analogs|
|US20020107289||Oct 19, 2001||Aug 8, 2002||Serhan Charles N.||Regulation of phospholipase D activity|
|US20020120013||Oct 19, 2001||Aug 29, 2002||Serhan Charles N.||Regulation of phospholipase D activity|
|US20020132847||Jan 11, 2002||Sep 19, 2002||Serhan Charles N.||Inhibition of TNF-alpha-initiated neutrophil response|
|US20020143069||Jan 11, 2002||Oct 3, 2002||Serhan Charles N.||Inhibition of TNF-alpha-initiated neutrophil response|
|US20020193431||Mar 1, 2002||Dec 19, 2002||Serhan Charles N.||Lipoxin analogs as novel inhibitors of angiogenesis|
|US20030032827||Jun 19, 2002||Feb 13, 2003||Serhan Charles N.||Lipoxin compounds and their use in treating cell proliferative disorders|
|US20030055275||Jun 20, 2002||Mar 20, 2003||Serhan Charles N.||Prevention of neutrophil recruitment|
|US20030060512||Sep 24, 2002||Mar 27, 2003||Madara James L.||Modulation of inflammation related to columnar epithelia|
|US20030069435||Jun 20, 2002||Apr 10, 2003||Serhan Charles N.||Prevention of neutrophil recruitment|
|US20030134901||Dec 2, 2002||Jul 17, 2003||Serhan Charles N.||Lipoxin compounds and their use in treating cell proliferative disorders|
|US20030166716||Nov 6, 2002||Sep 4, 2003||Serhan Charles N.||Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases|
|US20030191184||Dec 18, 2002||Oct 9, 2003||Serhan Charles N.||Novel approach to anti-microbial host defense with molecular shields with EPA and DHA analogs|
|US20030191332||Feb 13, 2003||Oct 9, 2003||Serhan Charles N.||Prevention of neutrophil recruitment|
|US20030195248||Dec 18, 2002||Oct 16, 2003||Serhan Charles N.||Novel approach to anti-microbial host defense with molecular shields with lipoxin compounds|
|US20030236423||Apr 1, 2003||Dec 25, 2003||Petasis Nicos A.||Trihydroxy polyunsaturated eicosanoids|
|US20040019110||Mar 20, 2001||Jan 29, 2004||Van Dyke Thomas E.||Lipoxin analogs and method for the treatment of periodontal disease|
|US20040053998||Jul 8, 2003||Mar 18, 2004||Serhan Charles N.||Lipoxin analogs as novel inhibitors of angiogenesis|
|US20040059144||Sep 12, 2003||Mar 25, 2004||Serhan Charles N.||Aspirin-triggered lipid mediators|
|US20040116408||Aug 12, 2003||Jun 17, 2004||Serhan Charles N.||Resolvins: biotemplates for novel therapeutic interventions|
|US20040151712||Jan 22, 2004||Aug 5, 2004||Madara James L.||Modulation of inflammation related to columnar epithelia|
|US20040192785||Mar 5, 2004||Sep 30, 2004||Serhan Charles N.||Inhibition of TNF-alpha-initiated neutrophil response|
|US20050075398||Aug 5, 2004||Apr 7, 2005||Bazan Nicolas G.||Neuroprotectin D1 protects against cellular apoptosis, stroke damage, alzheimer's disease and retinal diseases|
|US20050261255||Mar 16, 2005||Nov 24, 2005||Serhan Charles N||Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma|
|EP0736509A2||Apr 9, 1996||Oct 9, 1996||Sumitomo Chemical Company, Limited||Processes for preparing optically active alcohols and optically active amines|
|EP0736509B1||Apr 9, 1996||Nov 14, 2001||Sumitomo Chemical Company, Limited||Processes for preparing optically active alcohols and optically active amines|
|JPH05186342A||Title not available|
|WO1991016914A1||May 6, 1991||Nov 14, 1991||Bockow Barry I||Methods and preparations of stable, deodorized oils and pharmaceutical compositions thereof|
|WO1997019415A2||Nov 7, 1996||May 29, 1997||Cadis, Inc.||Search engine for remote object oriented database management system|
|WO1998019259A1||Oct 27, 1997||May 7, 1998||Ipf, Inc.||System and method for managing and serving consumer product related information over the internet|
|WO1998035469A2||Jan 23, 1998||Aug 13, 1998||The Sabre Group, Inc.||Information aggregation and synthesization system|
|WO1998046588A2||Apr 9, 1998||Oct 22, 1998||Neorx Corporation||Compounds and therapies for the prevention of vascular and non-vascular pathologies|
|WO1999006913A1||Jun 10, 1998||Feb 11, 1999||Arrowpoint Communications, Inc.||Content-aware flow switching|
|WO1999013417A1||Sep 8, 1998||Mar 18, 1999||Science Applications International Corporation||A system, method, and medium for retrieving, organising, and utilizing networked data|
|WO2001060778A2||Feb 16, 2001||Aug 23, 2001||The Brigham And Women's Hospital, Inc.||Aspirin-triggered lipid mediators|
|WO2003051350A1||Dec 18, 2002||Jun 26, 2003||The Brigham And Women's Hospital||Use of lipoxin analogs to promote cell defense against gram-negative infections|
|WO2003053423A2||Dec 18, 2002||Jul 3, 2003||The Brigham And Women's Hospital||Inhibition or prevention of infection by bacteria with epa, dha or analogs|
|1||A.J. Marcus, "Platelets: their role in hemostasis, thrombosis, and inflammation", Inflammation: Basic Principles and Clinical Correlates 1999, pp. 77-95.|
|2||A.P. Simopoulos, "Workshop on the essentiality of an recommended dietary intakes for omega-6 and omega-3 fatty acids", J. Am. Coll. Nutr. 1999, pp. 487-489.|
|3||Alami, et al., A versatile route to conjugated hydroxyl (E,Z,E,E)-Tetraenoic acids: highly chemo- and stereoselective synthesis of lipoxin B4 tetrahedro Asym. 8(17): 2949-2958, 1997.|
|4||Arita et al., "Stereochemical Assignment, Antiinflammatory Properties, and Receptor for the Omega-3 Lipid Mediator Resolvin E1", J. Exp. Med. 201(5): 713-722, 2005.|
|5||Arita, et al., "Resolvin E1, An Endogenous Lipid Mediator Derived from Omega-3 Eicosapentaenoic Acid, Protects Against 2, 4,6-Trinitrobenzene Sulfonic Acid-Induced Colitis", Proc. Natl. Acad. Sci, USA, 102(21): 7671-7676, 2005.|
|6||B.N. Cronstein et al., "A mechanism for the anti-inflammatory effects of corticosteriods: The glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1", Proc. Natl. Acad. Sci. 1992, pp. 9991-9995.|
|7||Babine, R.E. and S.L. Bender., "Molecular Recognition of Protein-Ligand Complexes: Applications to Design" Chem. Rev. 97:1359-1472 (1997).|
|8||Bannenberg, et al., "Molecular Circuits of Resolution: Formation and Actions of Resolvins and Protectins", Immunol. 174(7): 4345-4355, 2005.|
|9||Beamer L.J. et al. "Crystal structure of Human BPI and two bound phospholipids at 2.4 angstrom resolution", Science, vol. 276, 1997, pp. 1861-1864.|
|10||Bhaley, G. et al., Solid Phase Synthesis of Diverse Tetrahydro-1,4- Benzodiazepine-2-ones, Tetrahedron Letters 38(48):8375-8378 (1997).|
|11||Blaser, E. et al., "Asymmetrix Steering of oxa Diels-Alder Reactions with Silyloxydienes Employing Proline Esters as Chiral Auxillary Groups," Eur. J. Org. Chem. , 329-333, (1999).|
|12||Boland et al., "Stereospecific Syntheses and Spectroscopis Properties of Isomeric 2,4,6,8-Undecatetraenes. New Hydrocarbons from the Marine Brown Alga Giffordia Mitchellae", Helv. Chim. Acta 70;1025-1040, 1987.|
|13||C.N. Serhan et al, "Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils", Biochemistry, 1995, pp. 14609-14615.|
|14||C.N. Serhan et al., "Nomenclature of lipoxins and related compounds dervived from arachidonic acid and eicosapentaenoic acid", Prostaglandins ,1987, pp. 201-204.|
|15||C.N. Serhan et al., "Novel functional sets of lipid-derived mediators with Anti-Inflammatory Actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal anti-Inflammatory drugs and transcellular processing", J. Exp. Med., vol. 192, No. 8, 2000, pp. 1197-1204.|
|16||C.N. Serhan, et al., "Resolvins: A family of bioactive products of omega-3 fatty acids transformation circuits initiated by aspirin treatment that counter proinflammation signals", J. Exp. Med. , vol. 196, No. 8, pp. 1025-1037, 2002.|
|17||CA 101:19194 for VanRollins et al., Journal of Biological Chemistry,(1984) 259(9), pp. 5776-5783.|
|18||CA 119: 265901 for Reynaud et al., Analytical Biochemistry (1993), 214(1), pp. 165-170.|
|19||Canny, G. et al., "Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia", Proc. Natl. Acad., Sci., USA, vol. 99, No. 6, 2002, pp. 3902-3907.|
|20||Colgan, S.P .et al., "Defective in vitro motility of polymorphonuclear leuocytes of homozygote and heterozygote Chediak-Higashi cats", Vet. Immunol. Immunopathology, 1992, pp. 205-227.|
|21||Cooper, S.F., et al., "Identification of Antibacterial Fatty Acids from Phaeodactylum tricomtum grown in dialysis culture", The Faculty Press, 1985, pp. 28-36.|
|22||D.J. Hill et al., "Trout thrombocytes contain 12-but not 5-lipoxygenase activity", Biochem. Biophys. Acta 1999, pp. 63-70.|
|23||Dharmsathaphorn, K. et al., "Established intestinal cell lines as model systems for electrolyte transport studies", Methods in Enzymology, vol. 192, 1990, pp. 354-389.|
|24||Dioux, Laurent and Morris Srebnik, "Asymmetric Boron-Catalyzed Reactins", Chem Rev. 93:763-784, (1993).|
|25||Durantel et al., "Study of the mechamism of Antiviral Action of Iminosugar Derivatives against Bovine Viral Diarrhea Virus", J. Virology 75 (19): 8987-8998, 2001.|
|26||E.M. Hill, et al. "Identification and egg hatching activity of monohydroxy fatty acid eicosanoids in the barnacle Balanus balanoides", Abstract, XP-002200247, 1992.|
|27||Eckmann, L. et al., Epithelial cell secrete the chemokines interleukin-8 in response to bacterial entry, Infection and Immunity, vol. 61, No. 11, 1193, pp. 4569-4574.|
|28||Elsbach, P .et al., "Role of the bactericidal/permeability-increasing protein in host defence", Current Opinion in Immunology, vol. 10, No. 1, 1998, pp. 45-49.|
|29||Eritsland et al., "Effects of Highly Concentrated Omega-3 PUF As and Acetylsalicylic Acid, Alone and Combined, on Bleeding Time and Serum Liquid Profile", J. Oslo City Hosp., vol. 39 (8-9), pp. 97-101, 1989.|
|30||Evans, B.E. et al., "Design of Nonpetidal ligands for a Peptide Receptor: Cholecystokinin Antagonists", J. Med. Chem. 30:1229-1239 (1987).|
|31||Fletcher, M.D. and M.C. Campbell, "Partially Modified Retro-Inverso Peptides: Development, Sythesis, and Conformational Behavior," Chem. Rev., 98: 763-795, (1998).|
|32||G. Weissmann, "Aspirin", Sci. Am. 1991, pp. 84-90.|
|33||G. Xiao et al., "Analysis of hydroperoxide-induced tyrosyl radicals and lipoxygenase activity in aspirin-treated human prostaglandin H synthase-2", Biochemistry 1997, pp. 1836-1845.|
|34||G.E. Billman et al., "Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs", Circulation 99 , 99, pp. 2452-2457.|
|35||G.N. Levy, "Prostaglandin H synthases, nonsteriodal anti-inflammatory drugs, and colon cancer", FASEB J. 1997, pp. 234-247.|
|36||Ganz T. et al., "Antimicrobial peptides of phagocytes and epithelia", Seminars in Hematology, vol. 34, No. 4, 1997, pp. 343-354.|
|37||Garro-Hellon et al., "Mild and selective Palladium (0)-Catalyzed Deallylation of Allylic Amines, Allylamine and Diallylamines as Very Convenient Ammonia Equivalents for the Synthesis of Primary Amines", J. Org. Chem. 58: 6109-6113, (1993).|
|38||Golebiowski, A. and J. Jurczak, "Alpha-Amino-Beta-Hydroxy Acids in the Total Synthesis of Amino Sugars", Synlett, pp. 241-245, (Apr. 1993).|
|39||Gullier et al., "Linkers and Cleavage Stategies in Solid Phase Organic Synthesis and Combinatorial Chemistry", Chem. Rev. , 100:2091-2157, (2000).|
|40||H.J. George et al., "Expression purification and characterization of recombinant human Inductible prostaglandin G/H synthase from baculovirus-infected insect cells", Protein Expres. Purif. 1996, pp. 19-26.|
|41||H.R. Herschman, "Recent progress in the cellular and molecular biology of prostaglandin synthesis", Trends Cardiovasc. Med. , 1998, pp. 145-150.|
|42||Hanessia, S. et al., "Design and Synthesis of Conformationally Constraines Amino Acids as Versatile Scaffolds and Peptide Manners", Tetrahedron Lett., 53:12789-12854, (1997).|
|43||Higuchi, R. et al., "Kinetic PCR analysis: real time monitoring of DNA amplification reactions", "Biotechnology", vol. 11, 1993, pp. 1026-1030.|
|44||Hill, E.M., Proc R. Soc. London Ser. B., 247 (1318) pp. 41-46, 1992.|
|45||Hong, et al., "Novel Docosatrienes and 17S-Resolvins Generated from Docosahexaenoic Acid in Murine Brain, Human Blood, and Glial Cells, Autacoids in Anti-Inflammation", J. Biol. Chem. 278(17): 14677-14687, 2003.|
|46||Hoyng, C.F. and A.D. Patel, "Aldehyde Components for use in Four-Component Condensation ("4CC") UGI Reaction Peptide Synthesis," Tetrahedron Lett., 21:4795-4798, (1980).|
|47||Humphrey, J.M. and A.R. Chamberlin, "Chemical Synthesis of Natural Product Peptides Coupling Methods for the Incorporation of noncoded Amino Acids into Peptides," Chem. Rev. , 97;2243-2266, 91997).|
|48||Iacoviello et al., "Modulation of Fibrinolytic Response to Venous Occulusion in Humans by a Combination of Low-Dose Aspirin and n-3 PUFAs", Arteriosclerosis Thrombosis, vol. 10, pp. 1191-1197, 1992.|
|49||Ikeda et al., "Chiral Allenylboronic Esters as Practical Reagent for Enantioselective Carbon-Carbon Bond formation Facile Synthesis of (-) Ipsenol", J. Am. Chem, Soc., 108;483-4486, 1986.|
|50||J. Claria et al., "Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions", Proc. Natl. Acad. Sci., USA, 1995, pp. 9475-9479.|
|51||J.H. Capdevila et al., "The highly stereoselective oxidation of polyunsaturated fatty acids by cytochrome P450BM-3", J. Biol. Chem. 1996, pp. 22663-22671.|
|52||K. Gronert, et al., "Transcellular regulation of eicosanoid biosynthesis", Eicosanoid Protocols 1999, pp. 119-144.|
|53||K. Node et al., "Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids", Science 1999, pp. 1276-1279.|
|54||Karanian, J.W., et al., "Physiological functions of hydroxyl-docosahexaenoic acid", Abstract, XP-002200246, 1993.|
|55||Knapp, Howard R., et al., "Bactericidal Effects of Polyunsaturated Fatty Acids", The Journal of Infectious Diseases, vol. 154, No. 1, 1986 pp. 84-94.|
|56||Konig et al., "Synthesis of N-Tert-Alkylglyxolic Acid Amides", Syntheses, pp. 1233-1234, (1993), [ In German, English language abstract of 1 st page of article].|
|57||L. De. Montarby, et al. "Synthesis stereoselectives de metabolites hydroxyles d'acides gras polinsatures", Bulletin De La Societe Chimique de France, No. 3, pp. 419-432, 1989.|
|58||Lau et al., "Effects of Fish Oil Supplementation on Non-Steroidal Anti-Inflammatory Drug (NSAID) Requirement in Patients with Mild Rheumatoid Arthritis-A Double-Blind Placebo Controlled Study", British Journal of Rheumatology, vol. 32 (11), pp. 982-989. 1993.|
|59||Levy, O. , "A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein", Antimicrobial Agents and Chemotherapy, vol. 44, No. 11, 2000, pp. 2925-2931.|
|60||Levy, O., "Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents", Blood, vol. 96, No. 8, 2000, pp. 2664-2672.|
|61||Lockhart, D.J. et al., "Expression monitoring by hybridixation to high-density oligonucleotide arrays", Nature Biotechnology, vol. 14, No. 13, 1996, pp. 1675-1680.|
|62||M. Ligo et al., "Inhibitory effects of docosahexaenoic acid on colon carcinoma 26 metastasis to the lung", Br. J. Cancer, pp. 650-655, 1997.|
|63||M. Yamane, et al., "Docosahexaenoic/arachidonic acid omega-hydroxylation system and differentiation in the human clonic adenocarcinoma cell line, Caco-2", Cancer Letters, vol. 122, pp. 51-59, 1998.|
|64||M.R. Buchanan et al., "Regulation of endothelial cell and platelet receptor-ligand binding by the 12- and 15-lipoxygenase monohydroxides, 12-, 15-HETE and 13-HODE", Prostaglandins Leukot. Essent. Fatty Acids 1998, pp. 339-346.|
|65||Marcheselli, et al. "Novel Docosanoids Inhibit Brain Ischemia-Reperfusion-Mediated Leukocyte Infiltration and Pro-Inflammatory Gene Expression", J. Biol. Chem. 278(44): 43807-43817, 2003.|
|66||Marx et al., "Synthetic Design for Combinatorial Chemistry. Solution and Polymer-Supported Synthesis of Polycyclic Lactams by Intramolecular Cyclization of Azomethane Ylides," J. Chem. Soc., 119:6153-6167, (1997).|
|67||Mehta et al., "Structure-Activity Relationship of a New Class of Anti-Hepatitis B Virus Agents", Antimicrobial Agents and Chemotherapy, 46(12):4004-4008 (2002).|
|68||Miller et al., Lipids, Chemical Abstract 112:117062, pp. 998-1003, 1989.|
|69||N. Chiang et al., "Aspirin-triggered 15-epl-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: Development of a specific 15-epi-LXA4 ELISA", J. Pharmacol. Exp. Ther. ,1998, pp. 779-790.|
|70||N. Chiang et al., "Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion", J. Clin. Invest., 1999, pp. 309-316.|
|71||Nicolaou et al., "Lipoxins and Related Eicosanoids: Biosynthesis, Biological Properties and Chemical Synthesis," Angew. Chem. Ed. Engl. 30: 1100-1116, (1991).|
|72||Nicolaou et al., "Novel IBX-Mediated Process for the Synthesis of Amino Sugars and Libraries Thereof", Angew. Chem. Int. Ed. Engl., 39:2525-2529, (2000).|
|73||P. Needleman et al., "The discovery and function of COX-2", J. Rheumatol, 1997, pp. 6-8.|
|74||P.M. Ridker et al., "Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men", N. Engl. J. Med. 1997, pp. 973-979.|
|75||Pfaffi, M.W., "A new mathematical model for relative quantification in real-time RT-PCR", Nucleic Acids Research, vol. 29, No. 9, 2001, pp. 2002-2007.|
|76||R. Marchioloi, "Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial", Lancet 1999, pp. 447-455.|
|77||R.T. Ruettinger et al., "Epoxidation of unsaturated fatty acids by a soluble cytochrome P-45-dependent system from Bacillus megaterium", J. Biol. Chem. 1981, pp. 5728-5734.|
|78||Rao et al, "Comparative Pharmacology of Cyclooxygenase Inhibitors on Platelet Function", Prostaglandins Leukot. Med., vol. 18 (1), pp. 119-131, 1985.|
|79||S. Sethi et al., "Inhibition of phagocyte-endothelium interactions by oxidized fatty acids: A natural anti-inflammatory mechanism?", J. Lab. Clin. Med. 1996, pp. 27-38.|
|80||Serhan et al., Resolvins, Docosatrienes, and Neuroprotectins, Novel Omega-3-Derived Mediators, and Their Aspirin-Triggered Endogenous Epimers: An Overview of Their Protective Roles in Catabasis, Prostaglandins Other Lipid Mediat. 5543, 1-18, 2004.|
|81||Serhan, "A Search for Endogenous Mechanisms of Anti-Inflammation Uncovers Novel Chemical Mediators: Missing Links to Resolution", Histochem Cell Biol. 122(4): 305-321, 2004.|
|82||Serhan, "Novel Eicosanoid and Docosanoid Mediators: Resolvins, Docosatrienes, and Neuroprotectins", Curr Opin Clin Nutr Metab Care, 8(2): 1-7, 2005.|
|83||Serhan, "Novel Omega-3-Derived Local Mediators in Anti-Inflammation and Resolution", Pharmacol. Ther. 105(1): 7-21, 2005.|
|84||Serhan, et al., "Novel Endogenous Small Molecules as the Checkpoint Controllers in Inflammation and Resolution: Entrée for Resoleomics" Rheum Dis Clin North Am. 30(1): 69-95, 2004.|
|85||Serhan, et al., "Novel Pathways and Endogenous Mediators in Anti-Inflammation and Resolution", Chem Immunol Allergy, 83: 115-145, 2003.|
|86||Serhan, et al., "Resolvins: a family of bioactive products of omega-3 fatty acids transformation circuits initiated by aspirin treatment that counter proinflammation signals", J. Exp. Med., vol. 196, No. 8 pp. 1025-1037, 2002.|
|87||Serhan, et al., Resolvins, Docosatrienes and Neuroprotectins, Novel Omega-3 Derived Mediators and Their Endogenous Aspirin-Triggered Epimers, Lipids, vol. 39, pp. 1125-1132, 2004.|
|88||T. Kato, et al., "Production of Hydroxy Unsaturated Fatty Acids Using Crude Lipoxygenase Obtained from Infected Rice Plants", Bull. Chem. Soc. Jpn., vol. 69, pp. 1663-1666, 1996.|
|89||T. Yokomizo et al., "A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis", Nature, 1997, pp. 620-624.|
|90||T.H. Lee et al., "Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product", J. Biol. Chem. 1984, pp. 2383-2389.|
|91||Takeshi Terano, Ensho, Chemical Abstract 107:22439, pp. 63-71, 1987.|
|92||Taylor, C.T. et al., "Critical role of cAMP response element binding protein expression in hypoxia-elicited induction of epithelial tumor necrosis factor-a", J. Biol. Chem., vol. 274, No. 27, 1999, pp. 19447-19454.|
|93||Terano T. et al., "Eicosapentaenoic acid and docosahexaenoic acid inhibit vascular smooth muscle cell proliferation by inhibiting phosphorylation of Cdk2-cyclinE complex", Biochem. Biophys. Res. Comm., vol. 254, pp. 502-506.|
|94||Van Dyke, et al., "Resolution of Inflammation: A New Paradigm for the Pathogenesis of Periodontal Diseases", J. Dent. Res., 82(2): 82-90, 2003.|
|95||Vu Bois e tal., "Novel, Stereoselcetive Synthesis of 2 Amino Saccharides", J. Am. Chem. Soc. 119: 3179-3180, 1997.|
|96||W.E.M. Lands, "Proceedings of the AOCS Short Course on Polyunsaturated Fatty Acids and Eicosanoids", American Oil Chemists' Society 1987.|
|97||Weersink, A., et al., "Human granulocytes express a 550-kDa lipopolysaccharide-binding protein on the cell surface that is identical to the bactericidal/permeability-increasing protein", J. Immunology, vol. 150, No. 1, 1993, pp. 253-263.|
|98||Weiss, J. et al., "Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes", J. Biol. Chem., vol. 253, No. 8, 1987, pp. 2664-2672.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US7582785||Mar 29, 2005||Sep 1, 2009||University Of Southern California||Trihydroxy polyunsaturated eicosanoid derivatives|
|US7585856||Aug 12, 2003||Sep 8, 2009||The Brigham And Women's Hospital, Inc.||Resolvins: Biotemplates for novel therapeutic interventions|
|US7709669||Jan 18, 2006||May 4, 2010||The Brigham And Women's Hospital, Inc.||Aspirin-triggered lipid mediators|
|US7737178||Dec 18, 2008||Jun 15, 2010||The Brigham And Woman's Hospital, Inc.||Aspirin-triggered lipid mediators|
|US7741368||Feb 14, 2006||Jun 22, 2010||The Brigham And Women's Hospital, Inc.||Approach to antimicrobial host defense with molecular shields with EPA and DHA analogs|
|US7759395||Mar 16, 2005||Jul 20, 2010||The Brigham And Women's Hospital, Inc.||Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma|
|US7803557||Mar 10, 2008||Sep 28, 2010||The Brigham And Women's Hospital, Inc.||Methods for identification of eicosapentaenoic acid analogs using anti-inflammatory receptors|
|US7872152||Aug 9, 2007||Jan 18, 2011||The Brigham And Women's Hospital, Inc.||Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma|
|US7902257||May 20, 2009||Mar 8, 2011||University Of Southern California||Trihydroxy polyunsaturated eicosanoid|
|US8273792||Oct 3, 2006||Sep 25, 2012||The Brigham And Women's Hospital, Inc.||Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers|
|US8349896||Feb 17, 2010||Jan 8, 2013||The Brigham And Womens's Hospital, Inc.||Aspirin-triggered lipid mediators|
|US8461201||Mar 7, 2011||Jun 11, 2013||University Of Southern California||Trihydroxy polyunsaturated eicosanoid derivatives|
|US8481772||Feb 28, 2012||Jul 9, 2013||University Of Southern California||Trihydroxy polyunsaturated eicosanoid derivatives|
|US8569542||Jan 15, 2011||Oct 29, 2013||The Brigham And Women's Hospital, Inc.||Use of docosatrienes, resolvins, and their stable analogs in the treatment of airway diseases and asthma|
|US8605786 *||Sep 3, 2008||Dec 10, 2013||The Regents Of The University Of California||Hierarchical motion vector processing method, software and devices|
|US8636986||Nov 17, 2006||Jan 28, 2014||The Forsyth Institute||Treatment and prevention of bone loss using resolvins|
|US8802874||Jul 8, 2013||Aug 12, 2014||University Of Southern California||Trihydroxy polyunsaturated eicosanoid derivatives|
|US8933270||Oct 28, 2013||Jan 13, 2015||The Brigham And Women's Hospital, Inc.||Use of docasatrienes, resolvins, and their stable analogs in the treatment of airway diseases and asthma|
|US9146240 *||Sep 4, 2013||Sep 29, 2015||Saint Louis University||Systems and methods for determining a C-peptide receptor, C-peptide receptor, and methods of using same|
|US9364454||Sep 24, 2012||Jun 14, 2016||The Brigham And Women's Hospital, Inc.||Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers|
|US20050228047 *||Mar 29, 2005||Oct 13, 2005||Petasis Nicos A||Trihydroxy polyunsaturated eicosanoid derivatives|
|US20050238589 *||Apr 14, 2005||Oct 27, 2005||Van Dyke Thomas E||Methods and compositions for preventing or treating periodontal diseases|
|US20060128804 *||Feb 14, 2006||Jun 15, 2006||Brigham And Women' Hospital||Novel approach to antimicrobial host defense with molecular shields with EPA and DHA analogs|
|US20060293288 *||Jan 5, 2006||Dec 28, 2006||Serhan Charles N||Use of resolvins to treat gastrointestinal diseases|
|US20070049639 *||Jan 18, 2006||Mar 1, 2007||Serhan Charles N||Aspirin-triggered lipid mediators|
|US20080280980 *||Nov 17, 2006||Nov 13, 2008||Trustees Of Boston Univeristy||Treatment and Prevention of Bone Loss Using Resolvins|
|US20090156673 *||Oct 3, 2006||Jun 18, 2009||The Brigham And Women's Hospital, Inc. Corporate Sponsored Research & Licensing||Anti-inflammatory actions of neuroprotectin d1/protectin d1 and it's natural stereoisomers|
|US20090180961 *||Mar 10, 2008||Jul 16, 2009||Serhan Charles N||Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs|
|US20100016432 *||Jul 8, 2009||Jan 21, 2010||The Brigham And Women's Hospital, Inc.||Resolvins: biotemplates for novel therapeutic interventions|
|US20110129015 *||Sep 3, 2008||Jun 2, 2011||The Regents Of The University Of California||Hierarchical motion vector processing method, software and devices|
|US20140072977 *||Sep 4, 2013||Mar 13, 2014||Saint Louis University||Systems and Methods for Determining a C-Peptide Receptor, C-Peptide Receptor, and Methods of Using Same|
|U.S. Classification||435/7.2, 435/7.24|
|International Classification||A61K, G01N33/50, G01N33/53, G01N33/567|
|Cooperative Classification||G01N33/566, G01N2333/715, G01N33/505, G01N33/5047, G01N33/5023, G01N2333/4703, G01N2500/04, G01N33/5032, G01N33/5041, G01N2333/726|
|European Classification||G01N33/50D2F2, G01N33/50D2E8, G01N33/50D2E14, G01N33/50D2E2, G01N33/50D2F2B, G01N33/566|
|Oct 12, 2005||AS||Assignment|
Owner name: BRIGHAM AND WOMEN S HOSPITAL, INC., THE, MASSACHUS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SERHAN, CHARLES N.;ARITA, MAKOTO;REEL/FRAME:016876/0426
Effective date: 20051004
|Sep 12, 2011||FPAY||Fee payment|
Year of fee payment: 4
|Sep 11, 2015||FPAY||Fee payment|
Year of fee payment: 8